A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.

Also called NCT03358030

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 213 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03358030
  • EudraCT 2017-002165-21
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03358030. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-26 (actual); primary completion 2019-07-10 (actual). Results posted on 2023-01-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
Acronym
EMERALD
Condition
End-stage Renal Disease (ESRD)
Intervention (Drug)
ISIS 416858
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03358030
Content hash
362d0511b1c57affb4b7016d1438086d3b230266ec09a404d9e5ffb685c4294b